ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00322634
Recruitment Status : Completed
First Posted : May 8, 2006
Last Update Posted : September 19, 2012
Sponsor:
Information provided by (Responsible Party):
New Mexico Cancer Care Alliance

May 5, 2006
May 8, 2006
September 19, 2012
February 2006
July 2011   (Final data collection date for primary outcome measure)
Disease Progression [ Time Frame: 2 years ]
Not Provided
Complete list of historical versions of study NCT00322634 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors
Investigator Initiated Trial: Prospective Study of Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors
The use of performance status and LDH in combination can predict patient survival more accurately than physician clinical impression or the patients' own feelings about their survival
Patients with incurable cancer frequently ask their doctors for an estimate of survival. Such estimates can assist patients in making decisions about how best to spend their time and energy. Survival estimates are also required when considering patients with incurable cancer for experimental treatments. However, such estimates are difficult to make. There is some data to suggest that a simple clinical measure, the performance status, combined with a laboratory blood test, the LDH, may assist in making the survival estimate more realistic. This study is designed to test if this is the case, using patients with metastatic lung, breast, colorectal, prostate, or pancreatic cancer or patients with cancer of unknown primary who have exhausted life-prolonging therapy. These patients will be asked to consent to entering this study. Their performance status will be assessed by the Karnofsky and WHO scales, they will be asked to have their blood tested for LDH and they and their doctor will be asked to estimate their survival. After study entry they will be allowed to receive palliative radiotherapy, surgery or systemic therapy as indicated including protocol treatment. After study entry, the only other requirement is that the date of the patients death be reported so that the duration of survival can be compared with the doctors and patients estimate and correlated with the performance status and LDH.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Patients with metastatic solid tumors.
Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
375
July 2011
July 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. All patients must be at least 18 years of age
  2. All patients must have documented incurable metastatic cancer
  3. All patients must have exhausted any treatments which are known to prolong survival in their disease, or have elected not to receive further life-prolonging therapy. Specifically, patients with the following are eligible:

    1. Non-small cell lung cancer patients after third systemic therapy
    2. Small cell lung cancer patients after second systemic therapy
    3. Breast cancer patients after third cytotoxic therapy (does not include hormonal therapy)
    4. Colorectal cancer patients after second systemic therapy
    5. Hormone refractory prostate cancer patients after first cytotoxic therapy
    6. Cancer of unknown primary
    7. Pancreatic cancer patients after first systemic therapy
  4. The use of systemic (chemotherapy, immunotherapy) or local treatments (XRT) for palliation of symptoms is allowed
  5. Patients with a history of previous cancers are allowed
  6. Patients with a history of other significant disease (e.g. heart disease, COPD, etc.) are allowed
  7. All patients must sign informed consent

Exclusion Criteria:

  1. Patients with acute or chronic leukemia, Hodgkin's disease, or non-Hodgkins lymphoma are excluded
  2. Patients who do not sign informed consent are excluded
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00322634
INST 0535C
Yes
Not Provided
Not Provided
New Mexico Cancer Care Alliance
New Mexico Cancer Care Alliance
Not Provided
Principal Investigator: Malcolm Purdy, MD Hematology & Oncology Associates
New Mexico Cancer Care Alliance
August 2011